Tucson, Arizona / January 27, 2025 — Aspiro Therapeutics, a pioneering biopharmaceutical company dedicated to developing innovative treatments for obstructive lung diseases, announced that its CEO, James Lovgren, will attend the BIO CEO & Investor Conference 2025. The conference, hosted by the Biotechnology Innovation Organization (BIO), is one of the industry’s premier events, bringing together leading executives, investors, and biotech innovators.
Held from February 10–11, 2025, in New York City, the conference provides a unique opportunity to connect with stakeholders shaping the future of biotechnology. Mr. Lovgren will represent Aspiro Therapeutics, engaging with potential partners and investors as the company advances its groundbreaking CC16-derived peptidomimetic therapy for asthma and COPD.
“The BIO CEO & Investor Conference is a vital platform to foster collaborations and explore strategic opportunities in the biotech ecosystem,” said James Lovgren, CEO and Co-Founder of Aspiro Therapeutics. “I look forward to meeting with key stakeholders to discuss the future of respiratory care and share Aspiro’s progress toward revolutionizing treatment for obstructive lung diseases.”
For more information about the BIO CEO & Investor Conference 2025, visit bcic.bio.org.
![2025 RIS showcase company_banner-signature-650 x 150 (2)[63]](https://aspirotx.com/wp-content/uploads/elementor/thumbs/2025-RIS-showcase-company_banner-signature-650-x-150-263-r4ct5hpv3cumv4qvdn3anpf886awyr43mq6b3gm03i.jpg "2025 RIS showcase company_banner-signature-650 x 150 (2)[63]")
